These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27548034)

  • 1. Vaccination Against Human Papilloma Viruses Leads to a Favorable Cytokine Profile of Specific T Cells.
    Luckau S; Wehrs TP; Brandau S; Horn PA; Lindemann M
    J Immunother; 2016 Oct; 39(8):316-20. PubMed ID: 27548034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
    Ramos CA; Narala N; Vyas GM; Leen AM; Gerdemann U; Sturgis EM; Anderson ML; Savoldo B; Heslop HE; Brenner MK; Rooney CM
    J Immunother; 2013 Jan; 36(1):66-76. PubMed ID: 23211628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
    Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
    Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
    Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
    Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
    Al-Taei S; Banner R; Powell N; Evans M; Palaniappan N; Tabi Z; Man S
    Cancer Immunol Immunother; 2013 Dec; 62(12):1821-30. PubMed ID: 24146146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD8
    Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
    Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.
    Garcia-Bates TM; Kim E; Concha-Benavente F; Trivedi S; Mailliard RB; Gambotto A; Ferris RL
    J Immunol; 2016 Mar; 196(6):2870-8. PubMed ID: 26851223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
    Farhat S; Nakagawa M; Moscicki AB
    Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Response of Human T-Lymphocytes by Dendritic Cells Pulsed with HPV16E7 and Pleurotus sajor-caju-β-glucan (PBG).
    Roopngam PE
    Iran J Immunol; 2018 Dec; 15(4):246-255. PubMed ID: 30593739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
    Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
    Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.
    Lee SY; Kang TH; Knoff J; Huang Z; Soong RS; Alvarez RD; Hung CF; Wu TC
    Cancer Immunol Immunother; 2013 Jul; 62(7):1175-85. PubMed ID: 23615841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.
    Bourgault Villada I; Moyal Barracco M; Berville S; Bafounta ML; Longvert C; Prémel V; Villefroy P; Jullian E; Clerici T; Paniel B; Maillère B; Choppin J; Guillet JG
    Clin Exp Immunol; 2010 Jan; 159(1):45-56. PubMed ID: 19843089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ; Heusinkveld M; Ramwadhdoebe TH; Löwik MJ; van der Hulst JM; Goedemans R; Piersma SJ; Kenter GG; van der Burg SH
    Cancer Res; 2010 Apr; 70(7):2707-17. PubMed ID: 20233872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Essahsah F; Fathers LM; Offringa R; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; van der Burg SH; Melief CJ
    N Engl J Med; 2009 Nov; 361(19):1838-47. PubMed ID: 19890126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
    Bubenik J
    Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
    de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
    Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.